Dr. Stelios Papadopoulos is a co-founder and Chairman of the Board of Exelixis, Inc., Chairman of the Board of Regulus Therapeutics, Inc., and a member of the Board of Directors of Biogen Idec, Inc., BG Medicine, Inc., and Joule Unlimited, Inc. He is also a co-founder, member of the Board, and at times Chairman, of both, Anadys Pharmaceuticals, Inc. (acquired by Hoffman – La Roche in 2011) and Cellzome, Inc. (acquired by GlaxoSmithKline in 2012). In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke Medicine.

Dr. Stelios Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in 2006 after six years with the firm where as an investment banker he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was the biotechnology analyst of Donaldson, Lufkin & Jenrette.

Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University School of Medicine. Dr. Papadopoulos holds an M.S. in physics, a Ph.D. in biophysics and an M.B.A. in finance, all from New York University.